ライフサイエンスコーパス: disabling stroke

1 ] patients, with no mortality and one (1.7%) disabling stroke.

2 62% reduction in the secondary end point of disabling stroke.

3 ncluded stroke and the composite of death or disabling stroke.

4 oint consisted of 5-year all-cause death and disabling stroke.

5 rgery with respect to all-cause mortality or disabling stroke.

6 is a wasted opportunity to prevent recurrent disabling stroke.

7 rimary end point was death from any cause or disabling stroke.

8 ess, Society of Thoracic Surgeons score, and disabling stroke.

9 respect to the primary end point of death or disabling stroke.

10 iveness, for patients and caregivers after a disabling stroke.

11 al stroke, and 37 versus 84 others had a non-disabling stroke.

12 or reinfarction; and death, reinfarction or disabling stroke.

13 hagic stroke and result in a similar rate of disabling stroke.

14 years, including a 95% overall freedom from disabling stroke.

15 headache and loss of smell, to confusion and disabling strokes.

16 .53, 1.02-2.31, p=0.04), but were mainly non-disabling strokes.

17 revolutionized the stroke treatment for most disabling strokes.

18 was associated with low mortality (2.1%), no disabling stroke (0.0%), and fully percutaneous access a

19 pared with surgery, had a lower incidence of disabling stroke (0.5% vs. 1.7%), bleeding complications

20 e no differences in 30-day mortality (1.3%), disabling stroke (0.8%), or readmission (10.7%).

21 death (80 [22.3%] vs 70 [20.2%]; p=0.40) or disabling stroke (10 [3.1%] vs 16 [5.0%]; p=0.23) were s

22 2.76, 95% CI 1.17-6.51; p=0.021; HR for non-disabling stroke 3.00, 1.10-8.36; p=0.031), but we did n

23 3%), there were 3 strokes (10%), including 1 disabling stroke (3.3%), 1 death (3.3%), and 1 periproce

24 chical occurrence of: 1) all-cause death; 2) disabling stroke; 3) disease-related hospitalizations an

25 The number of fatal or disabling strokes (52 vs 49) and cumulative 5-year risk

26 stroke 2.98, 1.29-6.93; p=0.011; HR for non-disabling stroke 6.34, 1.45-27.71; p=0.014), but there w

27 mic stroke (18.2% vs 2.3%; P < 0.0001), more disabling strokes (8.8% vs 0.9%; P < 0.0001), and less c

28 association between EPD use and a proxy for disabling stroke among transfemoral TAVR patients betwee

29 Disabling stroke and myocardial infarction occurred in 2

30 respecified secondary end points of death or disabling stroke and other adverse events and hemodynami

31 nd point was, at 2 years, survival free from disabling stroke and reoperation to repair or replace th

32 e primary endpoint of all-cause mortality or disabling stroke and several secondary endpoints were as

33 stroke were 2.5% in each group for fatal or disabling stroke, and 5.3% with CAS versus 4.5% with CEA

34 point - a composite of death, reinfarction, disabling stroke, and ischemia-driven revascularization

35 had similar rate of the composite of death, disabling stroke, and myocardial infarction when compare

36 seline and postprocedure to identify stroke, disabling stroke, and other neurological outcomes.

37 points performed well in ascertaining death, disabling stroke, and pacemaker placement and were able

38 infarction [MI], emergency bypass procedure, disabling stroke, and target lesion revascularization).

39 At 30 days, four (2%) deaths, two (1%) disabling strokes, and two (1%) non-disabling strokes oc

40 h associated with clinical ischemic strokes, disabling strokes, and worse stroke recovery in patients

41 se two carotid artery procedures on fatal or disabling stroke are comparable.

42 term functional outcome and risk of fatal or disabling stroke are similar for stenting and endarterec

43 We compared rates of all-cause mortality or disabling stroke, associated clinical outcomes, and biop

44 The total number of deaths from any cause or disabling stroke at 1 year in the low-risk cohorts was 6

45 efficacy endpoint was all-cause mortality or disabling stroke at 1 year.

46 as associated with similar rates of death or disabling stroke at 2 years compared with commercial val

47 ferior to surgery for all-cause mortality or disabling stroke at 2 years.

48 e primary endpoint of all-cause mortality or disabling stroke at 2 years.

49 rimary end point was death from any cause or disabling stroke at 2 years.

50 t was a composite of death from any cause or disabling stroke at 24 months in patients undergoing att

51 e primary end point, a composite of death or disabling stroke at 24 months, using Bayesian methods.

52 spect to the composite end point of death or disabling stroke at 24 months.

53 The rates of disabling stroke at 30 days (0.8% vs. 0.1%, p = 0.005) a

54 en target-vessel revascularization (TVR), or disabling stroke at 30 days (4.6% versus 7.0%; relative

55 was the incidence of all-cause mortality or disabling stroke at 30 days.

56 as associated with reduced risk of recurrent disabling stroke at 5 years (HR 0.56, 95% CI 0.31-0.99;

57 cant difference in the incidence of death or disabling stroke at 5 years after TAVR as compared with

58 point was the rate of all-cause mortality or disabling stroke at two years.

59 in the incidence of death from any cause or disabling stroke between the TAVR group and the surgery

60 sent in the rates of death, reinfarction, or disabling stroke between the two groups.

61 n-group differences in the rates of death or disabling stroke, but reoperation for pump malfunction w

62 points included all-cause death, any stroke, disabling stroke, cardiovascular death, rehospitalizatio

63 stroke and a 73% relative risk reduction for disabling stroke compared to TAVR alone; a treatment eff

64 parable 3-year all-cause mortality and lower disabling stroke compared with patients treated with sur

65 with a reduced hazard of death and death or disabling stroke compared with SAVR, while rates of stro

66 Disabling stroke, death, transient ischemic attack, deli

67 for the major end points of 30-day death or disabling stroke; death or reinfarction; and death, rein

68 The primary outcome was in-hospital disabling stroke-defined as stroke associated with eithe

69 At 3 years, all-cause mortality or disabling stroke for TAVR was 5.7% and 8.0% for surgery

70 5% in the transfemoral access subgroup), and disabling strokes had occurred in 24 (2%), aortic valve

71 eduction in the hazard of all-cause death or disabling stroke (HR: 0.81; 95% CI: 0.68-0.96; P = 0.01)

72 nts (2.0%) in the treatment group, including disabling stroke in 2 patients; no additional events had

73 The primary endpoint was fatal or disabling stroke in any territory after randomisation to

74 of the trial is the 3-year rate of fatal or disabling stroke in any territory, which has not been an

75 EPD use was associated with a reduction in disabling stroke in both instrumental variable analysis

76 ortic valve replacement (SAVR) for death and disabling stroke in intermediate-risk patients with symp

77 We recruited patients with potentially disabling stroke in three stroke centres, performed magn

78 There were significantly more disabling strokes in unprotected patients at 30 days (1%

79 e of survival free of disabling stroke (with disabling stroke indicated by a modified Rankin score >3

80 ke is lower than in high-income regions, but disabling stroke is as prevalent.

81 The primary endpoint was fatal or disabling stroke (ischaemic or haemorrhagic), intracrani

82 oint was a composite of all-cause mortality, disabling stroke, life-threatening bleeding requiring tr

83 The secondary (disabling stroke, life-threatening bleeding, or all-caus

84 ty (Lotus, 1.9%; ES3, 1.8%; P=0.87), rate of disabling stroke (Lotus, 1.5%; ES3, 2.1%; P=0.62), or ma

85 Disabling stroke, myocardial infarction, and life-threat

86 or surgical rescue within 180 days; or major disabling stroke, myocardial infarction, or death from n

87 8], p<0.0001), 3.5% versus 6.1% for fatal or disabling strokes (net gain 2.5% [0.8-4.3], p=0.004), an

88 point was a hierarchical composite of death, disabling stroke, nondisabling stroke, and the number of

89 hierarchical composite that included death, disabling stroke, nondisabling stroke, and the number of

90 Disabling stroke occurred in 0.5% of the patients in the

91 All-cause mortality was 1.9%, and disabling stroke occurred in 1.8% at 30 days.

92 At 30 days, mortality was 1%, disabling stroke occurred in 2.5% of patients, and New Y

93 oint of 30-day mortality, re-infarction, and disabling stroke occurred in 27 (5%) on-site PA patients

94 Disabling stroke occurred in 47 participants (1.2%) in t

95 y was observed, although a small increase in disabling stroke occurred.

96 two (1%) disabling strokes, and two (1%) non-disabling strokes occurred.

97 eath, strokes, and the composite of death or disabling stroke, occurring at 1 year (early) or after 1

98 mary safety outcome was a composite of major disabling stroke or death from any cause within 30 days.

99 thout resulting in an increased incidence of disabling stroke or death in the short term.

100 re 34 (Kaplan-Meier estimate 4.0%) events of disabling stroke or death in the stenting group compared

101 Overall, 1% had disabling stroke or death procedurally (15 allocated to

102 ch option causes about 1% procedural risk of disabling stroke or death.

103 end point was survival at 2 years free from disabling stroke or device removal for malfunction or fa

104 flow LVAD with respect to survival free from disabling stroke or device removal for malfunction or fa

105 (3%) in the control group either had a major disabling stroke or died within 30 days.

106 LV thrombus may cause disabling stroke or other thromboembolic events in this

107 or the primary end point of survival free of disabling stroke or reoperation to replace or remove a m

108 ry end point was survival at 2 years free of disabling stroke or reoperation to replace or remove a m

109 as superior with respect to survival free of disabling stroke or reoperation to replace or remove a m

110 -flow pump group, remained alive and free of disabling stroke or reoperation to replace or remove a m

111 trial primary end point (survival free of a disabling stroke or reoperation to replace the pump for

112 Although the survival free of disabling stroke or reoperation to replace/remove a malf

113 oprimary clinical end point comprised death, disabling stroke, or heart failure-related rehospitaliza

114 hrough 12 months, were a composite of death, disabling stroke, or rehospitalization for heart failure

115 ed primary end point of death, reinfarction, disabling stroke, or target-vessel revascularization bec

116 ite adverse event rate (death, reinfarction, disabling stroke, or TVR) was greater after optimal PTCA

117 f the percentage of patients who died, had a disabling stroke, or were rehospitalized for heart failu

118 The 30-day mortality was 14%, with no disabling strokes, or repeat interventions.

119 Patients 4-6 weeks after TIA or non-disabling stroke (Oxford Vascular Study) underwent 5 min

120 t atrial fibrillation and higher risk of non-disabling stroke, permanent pacemaker implantation, and

121 hin 30 days was 3.0% (95% CI 2.4-3.9; 26 non-disabling strokes plus 34 disabling or fatal perioperati

122 ity rates were 3.5% vs 4.4% (P = 0.366), and disabling stroke rates were 1.5% vs 2.7% (P = 0.119), re

123 en treatment arms for all-cause mortality or disabling stroke remained broadly consistent over time:

124 I) 0.47 to 0.96, P = 0.031], as was death or disabling stroke (RR 0.68; 95% CI 0.50 to 0.92, P = 0.01

125 There were no significant differences for disabling stroke (S3 1.3% versus XT 3.1%, P=0.29) and al

126 performance in identifying trial-adjudicated disabling stroke (sensitivity 68.8%, specificity 99.0%,

127 antly reduce the primary end point of death, disabling stroke, serious bleeding, or cardiac arrest co

128 The primary CABANA end point (death, disabling stroke, serious bleeding, or cardiac arrest) o

129 The primary composite outcome was death, disabling stroke, serious bleeding, or cardiac arrest, a

130 primary end point was a composite of death, disabling stroke, serious bleeding, or cardiac arrest.

131 e primary endpoint was a composite of death, disabling stroke, serious bleeding, or cardiac arrest.

132 he primary outcome was a composite of death, disabling stroke, serious bleeding, or cardiac arrest.

133 ce the primary composite end point of death, disabling stroke, serious bleeding, or cardiac arrest.

134 primary end point was a composite of death, disabling stroke, serious bleeding, or cardiac arrest.

135 e reduction in the primary outcome of death, disabling stroke, serious bleeding, or cardiac arrest.

136 t, TAVR resulted in a lower rate of death or disabling stroke than surgery (hazard ratio, 0.79; 95% C

137 discharge to a nonhome location (a proxy for disabling stroke) that is likely to be causal in nature.

138 ccurred 55 months after surgery, and one non-disabling stroke three months after surgery.

139 myocardial infarction) and outcomes (stroke, disabling stroke, transient ischemic attack, major vascu

140 valuated the association between EPD use and disabling stroke using instrumental variable analysis wi

141 t arms for the primary end point of death or disabling stroke using trial data (hazard ratio, 0.83 [9

142 ortality at 30 days was 8%, with no cases of disabling stroke, valve embolization, or major/life-thre

143 The unadjusted rate of in-hospital disabling stroke was 0.7% among the EPD group and 0.9% i

144 The incidence of all-cause mortality or disabling stroke was 1.3% (95% CI, 0.3%-5.3%) at 30 days

145 the mortality rate was 4.2%, and the rate of disabling stroke was 1.7%; 1 (1.0%) patient had moderate

146 stroke was 82%, while freedom from severely disabling stroke was 89%.

147 Importantly, 2-year freedom from disabling stroke was 95%.

148 0.87 to 1.20), but the incidence of death or disabling stroke was higher after TAVR than after surger

149 Disabling stroke was less frequent with the Lotus valve

150 ery in all-cause mortality, the incidence of disabling stroke was lower with TAVR (0.6%) than surgery

151 The 90-day risk of fatal or disabling stroke was reduced in phase 2 (1 of 281 vs 16

152 The rate of death from any cause or disabling stroke was similar in the TAVR group and the s

153 complete 2-year primary endpoint of death or disabling stroke were 4.3% in the TAVR group and 6.3% in

154 d acute events, and long-term care following disabling stroke were presented in 2015 U.S. dollars.

155 At 5 years, the rates of death or disabling stroke were similar (TAVR, 31.3% vs surgery, 3

156 ate-risk patients, 5-year rates of death and disabling stroke were similar between S3 TAVR and SAVR.

157 es of intracranial haemorrhage and non-fatal disabling stroke were similar.

158 nosis showed a higher procedural risk of non-disabling stroke with stenting versus endarterectomy, bu

159 nd point was a composite of survival free of disabling stroke (with disabling stroke indicated by a m

160 e primary endpoint of all-cause mortality or disabling stroke, with event rates that were slightly be

161 early reduction in the composite of death or disabling stroke, with no difference at later follow-up.

162 Primary end point was all-cause mortality or disabling stroke within 12 months.